Association between direct measurement of active serum calcium and risk of type 2 diabetes mellitus: a prospective study

Zaccardi F a, Webb DR a, Carter P a, Pitocco D b, Khunti K a, Davies MJ a, Kurl S c, Laukkanen JA c,d

a Diabetes Research Centre, University of Leicester, Leicester, UK
b Diabetes Research Unit, Catholic University School of Medicine, Rome, Italy
c Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
d Lapland Central Hospital, Department of Internal Medicine, Rovaniemi, Finland

Word Count: Abstract 250; Text 2432

References: 38

Tables: 1; Figures: 1

Supplemental Data: 3 Tables and 2 Figures

Corresponding Author:

Dr Francesco Zaccardi
Diabetes Research Centre, Leicester General Hospital, Leicester, UK
Phone: +44 0116 258 4389 – Fax: +44 0116 258 4499
Email: frazac@fastwebnet.it

Keywords: Calcium; Ionized Calcium; Type 2 Diabetes Mellitus; Risk; Prospective Study
Abbreviations:

T2DM  Type 2 diabetes mellitus
iCa    Ionized calcium
BMI    Body mass index
HOMA-IR Homeostasis model assessment - Insulin resistance
FPG    Fasting plasma glucose
CRP    C-reactive protein
SD     Standard deviation
HR     Hazard ratio
Loge   Natural logarithm
CI     Confidence interval
SBP    Systolic blood pressure
PTH    Parathyroid hormone
ABSTRACT

BACKGROUND AND AIMS Previous prospective studies showing a positive association between serum calcium and incidence of type 2 diabetes mellitus (T2DM) have relied on total calcium or an indirect estimate of active, ionized calcium (iCa). We aimed to assess this relationship using a direct measurement of iCa.

METHODS AND RESULTS iCa and cardiometabolic risk factors were measured in a population-based sample of 2350 men without a known history of T2DM at baseline. Associations between iCa levels and incident cases of T2DM (self-reported, ascertained with a glucose tolerance test, or determined by record linkage to national registers) were estimated using Cox regression analyses adjusted for potential confounders. At baseline, mean (standard deviation) age was 53 (5) years and mean iCa 1.18 (0.05) mmol/L. During a median follow-up of 23.1 years, 140 new cases of T2DM were recorded. In a multivariable analysis adjusted for age, body mass index, systolic blood pressure, serum HDL-cholesterol, and family history of T2DM, there was no association comparing second (hazard ratio 0.84; 95% confidence interval 0.59–1.18), third (0.77; 0.52–1.14), or fourth (0.98; 0.69–1.39) vs first quartile of iCa (p for trend 0.538); further adjustment for C-reactive protein, physical activity level, and triglycerides did not change the estimates (p for trend 0.389).

CONCLUSION In this study, we did not find evidence of an association between direct measurement of active calcium and risk of T2DM. Further studies are needed to confirm our findings and define the relationship between factors influencing indirect calcium estimation and incident T2DM.
INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a metabolic disorder whose major clinical feature is hyperglycemia (1). Numerous recent studies have highlighted the complexity of its pathophysiology, including abnormal gut/β-cell cross-talk, insufficient insulin secretion, and a reduced insulin action in peripheral tissues (2).

Calcium plays an active role in both insulin secretion and its peripheral effects. Glucose-dependent insulin exocytosis is a calcium-regulated process, being dependent upon β-cell intracellular calcium concentration (3). Calcium is an established regulator of GLUT4 expression, a passive transporter essential for peripheral glucose uptake (4). As a consequence, abnormalities in calcium homeostasis could potentially affect glucose metabolism and contribute to the development of T2DM (5).

A possible association between calcium and T2DM risk has been explored in nutritional epidemiology studies: the available evidence, though, is limited because most studies are cross-sectional and did not adjust for important confounders (6). Similarly, cross-sectional and case-control studies investigating the relationship between calcium homeostasis and glucose metabolism have reported conflicting results (7–15); however, only a few studies have prospectively evaluated the association between serum calcium and risk of incident T2DM, suggesting that higher levels of serum calcium predict an increased risk of T2DM (16–18). These studies have relied either on total serum calcium or the indirect, albumin-corrected estimate of serum calcium: these measurements, however, only approximate the levels biological-active serum calcium (iCa) (19). Interestingly, a previous case-control study did not find an association between directly measured iCa and prevalent diabetes (11); similarly, in another small study, no association was found between direct iCa measurement and indices of diabetes control (15).
To our knowledge, the relationship between directly measured iCa and the risk of incident T2DM has not been investigated in a prospective study setting. Thus, our aim was to evaluate the risk of T2DM in a population-based study using direct measurement of iCa levels.
METHODS

This study was performed following the STROBE guidelines for observational studies (20).

Study population

The Kuopio Ischaemic Heart Disease risk factor study was designed to investigate risk predictors for atherosclerotic cardiovascular outcomes in a population-based sample of men from Eastern Finland. The subjects were a randomly selected sample of men 42 to 60 years of age resident in the town of Kuopio and its surrounding rural communities obtained from the national population register (21); baseline examinations were conducted between March 1984 and December 1989.

Of the 3433 invited, 2682 (78.1%) participated. In this study, participants were excluded if they were diagnosed with diabetes at baseline (n=162), defined as either having regular treatment with an oral hypoglycemic agent, insulin therapy, or having treatment only with diet while also having a fasting plasma glucose level of at least 7.0 mmol/L. We further excluded those subjects with missing baseline information on calcium (n=170). Therefore, data on 2350 participants were available for the analyses. Incident case of T2DM was defined as a self-reported physician-set diagnosis and/or fasting plasma glucose ≥7.0 mmol/L or 2-h oral glucose tolerance test plasma glucose ≥11.1 mmol/L at re-examination rounds 4, 11, and 20 years after baseline, and by record linkage to the national hospital discharge registry and to the Social Insurance Institution of Finland register for reimbursement of medicine expenses.

Assessment of risk factors
Prior to attendance at the baseline appointment, participants were instructed to abstain from drinking alcohol for a minimum of 3 days and from smoking for at least 12 hours. Fasting blood samples were taken following a 30-minute rest period in the supine position and collected using vacuum tubes (Terumo Venoject; Terumo, Tokyo, Japan).

The resting blood pressure was measured with a random-zero sphygmomanometer (Hawksley, Lancing England) by two trained nurses. A total of six measurements (3 supine, 1 standing, and 2 sitting) were taken following a 5 minute supine rest and blood pressure was taken as the mean of all six measurements. Baseline medical history, smoking habits, years of education, family history of T2DM (defined as positive if a first-degree relative of the subject had T2DM history), and drug therapy were assessed by self-administered questionnaires. The diagnosis of chronic diseases was checked during a medical examination by the internist. Detailed descriptions on physical activity estimation have been published previously (22). Body mass index (BMI) was computed as the ratio of weight in kilograms to the square of height in meters.

The measurement of serum active calcium concentrations (23) was made using ion selective electrodes (Microlyte 6, Kone, Finland; CV, 1.6%; reference interval, 1.16-1.32 mmol/l). Serum insulin level was determined using a radioimmunoassay kit (Novo Biolabs; Novo Nordisk, Bagsvaerd, Denmark). The serum samples were stored frozen at -80°C for 0.2-2.5 years. The values obtained were immunoreactive insulin as the assay has cross reactivity with proinsulin. A glucose dehydrogenase method (Merck, Darmstadt, Germany) was used to assess blood glucose after precipitation of proteins by trichloroacetic acid. Insulin resistance was estimated as follows: HOMA-IR = fasting plasma insulin (µU/mL) x fasting plasma glucose (FPG) (mmol/L)/22.5. The cholesterol contents of lipoprotein fractions and serum triglycerides were measured enzymatically (Boehringer Mannheim, Mannheim Germany). High-density lipoprotein (HDL) was separated from fresh samples by
ultracentrifugation and precipitation, low-density lipoprotein (LDL) was estimated as total cholesterol-HDL-triglycerides/5. Serum C-reactive protein (CRP) was measured with an immunometric assay (Immulite High Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA).

**Statistical analysis**

For all the analyses, natural logarithm ($\log_{e}$) transformed values of non-normal distributed variables (triglycerides, CRP, HOMA-IR, years of education, alcohol consumption, and physical activity) were used. Descriptive data are presented as means and standard deviations (SD) or medians and interquartile ranges for continuous variables, and percentages for categorical values. Correlation coefficients were calculated to assess the correlation between baseline calcium levels and other continuous variables, whereas mean differences between groups were calculated for categorical factors.

Analyses of the associations between iCa and incident T2DM involved Cox-regression modelling. The proportional hazards assumption was verified for all variables by inspection of the plots of the Schoenfeld residual for covariates. Shapes of association were assessed by plotting hazard ratios (HRs) estimated within quartiles of calcium relative to the bottom quartile against the mean calcium level in each quartile; 95% confidence intervals (CIs) were estimated from variances attributed to the groups to reflect the amount of information within each group (including the reference category (24)). To assess the independence of association between calcium and incident cases of T2DM, we calculated quartiles HRs with progressive adjustment for potential confounders selected on the basis of their previously established role as predictive factors. In model 1, we included age, BMI, systolic blood pressure (SBP), serum HDL-cholesterol, and family history of T2DM; in model 2, we added CRP, physical activity, and serum triglyceride concentrations. Model 3a
included variables in model 2 plus HOMA-IR, while model 3b variables in model 2 plus FPG.

All analyses were performed with Stata 13 (Stata Corp, College Station, TX, USA), and two-sided $P$-value $< 0.05$ was considered statistically significant.
RESULTS

Baseline characteristics and numbers of outcome events during follow-up

At baseline, mean (SD) age, BMI and iCa were 53 (5) years, 26.7 (3.4) Kg/m² and 1.18 (0.05) mmol/L, respectively. Baseline characteristics of the study population and correlation coefficients between iCa and other variables are reported in Table 1 and Supplemental Table S1, respectively. Levels of cardiometabolic risk factors (i.e., BMI, triglycerides, FPG, HOMA-IR) were higher in subjects who had developed T2DM during follow-up as compared to subjects who had not (Table 1).

During a median follow-up of 23.1 (interquartile range: 16.2–25.1) years, a total of 140 (5.9%) new cases of T2DM were recorded, with an unadjusted incidence rate of 2.89 (95% CI: 2.45–3.41) per 1000 person-years.

Calcium as risk factor for incident type 2 diabetes mellitus

The relationship between baseline calcium levels and incident T2DM, progressively adjusted for potential confounders, is shown in Figure 1 (HRs are reported in Supplemental Table S2). In multivariable analysis adjusted for age, BMI, SBP, serum HDL-cholesterol, and family history of T2DM (model 1), we did not find an association between iCa and risk of T2DM: compared to the first quartile of iCa, the HRs for the second, third, and fourth quartiles were 0.84 (95% confidence interval: 0.59–1.18), 0.77 (0.52–1.14), and 0.98 (0.69–1.39), respectively (p for trend 0.538; Figure 1 and Supplemental Table S2). The respective HRs, upon further adjustment for CRP, physical activity level, and triglycerides, were 0.89 (0.63–1.26), 0.79 (0.52–1.17), and 0.87 (0.61–1.26); p for trend 0.389. Similar nonsignificant associations were found after further inclusion of HOMA-IR (model 3a; p for trend 0.557) or FPG (model 3b; p for trend 0.330).
DISCUSSION

Our results indicate that, in this cohort of middle-age Finnish men, direct measurement of active, ionized serum calcium is not associated with incident T2DM.

T2DM is a major cause of morbidity and mortality in the developed and developing world (25). Although much progress has been made in describing its physiopathology, there is a growing interest in the identification of new biomarkers to help clarify its aetiology or define subjects at higher risk of developing T2DM. The relationship between calcium and glucose homeostasis has long been recognized, with case-control studies assessing calcium fractions dating back to 1960s (26). In parallel with observational work, experimental studies have described the role of calcium at the cellular and molecular level, clarifying fundamental second messenger functions in insulin secretion (3) and action (4, 27).

Previous non-prospective observational studies have reported conflicting results about calcium levels (plasma, total serum, or albumin-corrected serum concentrations) and glucose homeostasis. In T2DM subjects, calcium levels have been shown to be higher (10, 13) and associated with fasting glucose or insulin resistance (8, 9, 12); conversely, other studies have reported no relationship with markers of glucose control (15), insulin resistance (7), or insulin secretion (7, 9).

To our knowledge, only three studies have prospectively assessed the relationship between incident diabetes and calcium concentrations. The characteristics and a graphical summary of the results are reported in Supplemental Table S3 and Supplemental Figure S1. A large Norwegian study has assessed the association between non-fasting total serum calcium and risk of T2DM, cancer, and cardiovascular disease, showing a positive relationship with T2DM (16). However, this study has also shown no relationship between two single nucleotide polymorphisms associated with calcium concentration (rs1801725 and
rs17251221) and risk of diabetes. More recently, two other smaller studies have investigated the link between fasting albumin-corrected serum calcium and incident T2DM, reporting positive associations (17, 18). Of note, in both studies the Authors acknowledged as a major limitation the unavailability of direct measurement of iCa.

Direct measurement of active, ionized calcium is regarded as the gold standard of calcium measurement (19, 23, 28). In normal conditions, about 50% of total serum calcium is present in iCa form, 35-40% is bound to negatively charged amino acid residues of proteins, and the remaining 10-15% is linked to small organic molecules (i.e., bicarbonate, citrate, sulfate, phosphate, lactate) to form complexes (23); therefore, conditions modifying one or more of these compounds could potentially result in changes of calcium fractions. In particular, alterations in albumin concentration, blood pH, use of drugs, or fatty acids bound to albumin change the ratio between total and iCa (19). As the primary, most abundant negatively charged serum protein is albumin, a common equation is used to estimate the “albumin-adjusted” total calcium. This equation is derived from healthy volunteers, is valid only for specific combinations of total calcium and albumin assays within given reference intervals, and assumes a constant binding capacity of albumin (1g/dL albumin binds approximately 0.8 mg/dL calcium) (19, 23). In subjects with T2DM there are many factors potentially modifying calcium fractions. In particular, high levels of circulating free fatty acids are known to alter calcium-albumin binding (29) and are also associated with incident risk of T2DM (30). In this situation total or albumin-corrected estimation of serum calcium can be biased (11) (Supplemental Figure S2). Similarly, higher levels of plasma lactate are associated with incident T2DM (31) and could modify calcium fractions (28). Lastly, it is worth noting that adjustment for albumin concentration has been proposed for another biomarker associated with incident T2DM (fructosamine) (32, 33), although it is still unclear the appropriateness of such adjustment given (34).
Interestingly, our results are in line with a previous study showing no difference in direct iCa measurement comparing subjects with and without diabetes (11); notably, the Authors speculated that 'correction' of total calcium for serum albumin would not be appropriate because of an increased serum free fatty acids concentrations. Similarly, in another study, direct measurement of iCa was not associated with indices of diabetes control (15). Notwithstanding the different exposure assessment, our results could be related to heterogeneous characteristics between populations (i.e., age, sex, race, or genetic background); or due to the ascertainment of outcomes; or associated to statistical planning and analysis; or a combination of all these. Notably, inherited characteristics, along with environmental factors, could explain the low values of iCa in our population. In fact, at high latitudes cutaneous synthesis of vitamin D is reduced, thus potentially resulting in low calcium levels (35).

We should acknowledge some limitations and strengths of this study. First, a generalisation of our findings is defined by the study population, consisting of middle-age Finnish men only; these findings need to be confirmed in other ethnic groups and in females. Second, we could not correct for a possible regression dilution bias (36), as we had only baseline assessment of iCa values. Nonetheless, for covariates with available repeated measurements, we have observed a rather stable “phenotype” (33). Third, our study did not collect information about parathyroid hormone (PTH) and vitamin D for all participants; therefore, it was not possible to adjust for these variables or to exclude subjects at high risk of primary or secondary hyperparathyroidism, also implicated with glucose metabolism (5, 37). However, adjustment for PTH (or vitamin D) requires that such a variable is associated with T2DM independent of iCa (38), an assumption that needs to be verified. Fourth, as pH influences direct iCa measurement, it could be considered a confounder; this hypothesis
could not be tested in our analysis, lacking baseline pH data. Yet, up to our knowledge, no available evidence suggests a relationship between pH and T2DM. Whether pH is a confounding factor, however, should be verified in future studies. On the other hand, strengths of this study include the rigorous measurement of baseline risk factors and assessment of T2DM, the large and homogeneous community-based sample, and the long-term follow-up.

In conclusion, in our cohort of middle-age Finnish men, direct measurement of iCa levels were not associated with incident T2DM risk. Further studies are needed to confirm our findings and elucidate the relationship between calcium and glucose metabolism.
ACKNOWLEDGMENT

We thank the staff of the Kuopio Research Institute of Exercise Medicine and the Research Institute of Public Health, University of Eastern Finland, for data collection.

We acknowledge the support of the following institutes in this work: the National Institute for Health Research, Collaboration for Leadership in Applied Health Research and Care - East Midlands (NIHR CLARHC East Midlands); and the National Institute for Health Research (NIHR) Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospitals of Leicester and Loughborough University. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

We thank two anonymous reviewers for their helpful comments and suggestions.

CONTRIBUTION

FZ: conception of the idea, analysis of data, drafting of the manuscript.

DRW, PC, DP, KK, MJD: interpretation of data, critical revision of the manuscript for important intellectual content, drafting of the manuscript.

SK: acquisition of data, administrative and technical support.

JAL: conception of the idea, interpretation of data, critical revision of the manuscript for important intellectual content, drafting of the manuscript.

FZ had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

ETHICS

The study was approved by the Research Ethics Committee of the University of Eastern Finland. Each participant gave written informed consent.
CONFLICT OF INTEREST

KK has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme. He has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. KK has received funds for research, honoraria for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp & Dohme and Novo Nordisk.

MJD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen and as a speaker for Mitsubishi Tanabe Pharma Corporation. She has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis and Lilly.

All other Authors have no conflict of interests to disclose.

FUNDINGS

The research was supported by the National Institute for Health Research (NIHR) Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospitals of Leicester and Loughborough University. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
REFERENCES


FIGURE LEGENDS

FIGURE 1: Hazard ratios and 95% confidence intervals (bars) of type 2 diabetes mellitus by quartiles of baseline active calcium levels.

Legend: Variables included in the models. Model 1: Age, body mass index, systolic blood pressure, serum HDL-cholesterol and family history of type 2 diabetes mellitus; Model 2: Model 1 plus C-reactive protein, physical activity and serum triglyceride; Model 3a: Model 2 plus HOMA-IR; Model 3b: Model 2 plus fasting plasma glucose.
Supplemental Data

Association between direct measurement of active serum calcium and risk of type 2 diabetes mellitus: a prospective study

Zaccardi F a, Webb DR a, Carter P a, Pitocco D b, Khunti K a, Davies MJ a, Kurl S c, Laukkanen JA c,d

1 Diabetes Research Centre, University of Leicester, Leicester, UK
2 Diabetes Research Unit, Catholic University School of Medicine, Rome, Italy
3 Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
4 Lapland Central Hospital, Department of Internal Medicine, Rovaniemi, Finland

Supplementary Tables: 3
Supplementary Figures: 2
**Supplemental Table S1:** Unadjusted correlation coefficients (r) between active serum calcium and other baseline covariates.

<table>
<thead>
<tr>
<th>Variable</th>
<th>r or difference (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>0.065 (0.024, 0.105)</td>
<td>0.002</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>-0.061 (-0.101, -0.020)</td>
<td>0.003</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>-0.021 (-0.062, 0.019)</td>
<td>0.302</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/L)</td>
<td>0.114 (0.074, 0.154)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>-0.017 (-0.057, 0.024)</td>
<td>0.412</td>
</tr>
<tr>
<td>Logₑ Triglycerides (mmol/L)</td>
<td>-0.092 (-0.131, -0.051)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting plasma glucose (mmol/L)</td>
<td>-0.007 (-0.048, 0.033)</td>
<td>0.729</td>
</tr>
<tr>
<td>Logₑ C-reactive protein (mg/L)</td>
<td>-0.038 (-0.078, 0.003)</td>
<td>0.067</td>
</tr>
<tr>
<td>Logₑ HOMA-IR</td>
<td>0.039 (-0.002, 0.080)</td>
<td>0.061</td>
</tr>
<tr>
<td>Smoking (yes)</td>
<td>0.55% (0.18, 0.93)</td>
<td>0.004</td>
</tr>
<tr>
<td>Family history of diabetes (yes)</td>
<td>0.18% (-0.21, 0.58)</td>
<td>0.359</td>
</tr>
<tr>
<td>Logₑ Education (years)</td>
<td>-0.116 (-0.155, -0.076)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Logₑ Alcohol (g/week)</td>
<td>-0.008 (-0.052, 0.035)</td>
<td>0.707</td>
</tr>
<tr>
<td>Logₑ Physical activity (kcal/day)</td>
<td>0.001 (-0.040, 0.041)</td>
<td>0.976</td>
</tr>
</tbody>
</table>

Logₑ: Natural logarithm; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; HOMA-IR: Homeostatic model assessment of insulin resistance
### Supplemental Table S2: Hazard ratios (HRs) of type 2 diabetes mellitus, by quartiles of baseline active calcium serum levels.

<table>
<thead>
<tr>
<th>Model</th>
<th>Quartile 1 [0.88-1.15; 1.12]</th>
<th>Quartile 2 [1.16-1.18; 1.17]</th>
<th>Quartile 3 [1.19-1.21; 1.20]</th>
<th>Quartile 4 [1.22-1.50; 1.24]</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Cases/Participants</td>
<td>47/740</td>
<td>33/578</td>
<td>25/525</td>
<td>35/507</td>
</tr>
<tr>
<td>Model 1: HRs (95% CIs)</td>
<td>1.00 (0.74, 1.34)</td>
<td>0.84 (0.59, 1.18)</td>
<td>0.77 (0.52, 1.14)</td>
<td>0.98 (0.69, 1.39)</td>
</tr>
<tr>
<td>p-value</td>
<td>-</td>
<td>0.321</td>
<td>0.190</td>
<td>0.928</td>
</tr>
<tr>
<td>Model 2: HRs (95% CIs)</td>
<td>1.00 (0.74, 1.35)</td>
<td>0.89 (0.63, 1.26)</td>
<td>0.79 (0.52, 1.17)</td>
<td>0.87 (0.61, 1.26)</td>
</tr>
<tr>
<td>p-value</td>
<td>-</td>
<td>0.532</td>
<td>0.243</td>
<td>0.486</td>
</tr>
<tr>
<td>Model 3a: HRs (95% CIs)</td>
<td>1.00 (0.73, 1.36)</td>
<td>0.93 (0.65, 1.33)</td>
<td>0.80 (0.53, 1.21)</td>
<td>0.82 (0.56, 1.20)</td>
</tr>
<tr>
<td>p-value</td>
<td>-</td>
<td>0.718</td>
<td>0.291</td>
<td>0.317</td>
</tr>
<tr>
<td>Model 3b: HRs (95% CIs)</td>
<td>1.00 (0.74, 1.35)</td>
<td>0.87 (0.61, 1.23)</td>
<td>0.79 (0.53, 1.18)</td>
<td>0.86 (0.59, 1.23)</td>
</tr>
<tr>
<td>p-value</td>
<td>-</td>
<td>0.447</td>
<td>0.251</td>
<td>0.409</td>
</tr>
</tbody>
</table>

Covariates included in the analyses:

**Model 1:** Age, body mass index, systolic blood pressure, serum HDL-cholesterol and family history type 2 diabetes mellitus

**Model 2:** Model 1 plus C-reactive protein, physical activity and serum triglyceride

**Model 3a:** Model 2 plus HOMA-IR

**Model 3b:** Model 2 plus fasting plasma glucose
**Supplemental Table S3: Summary of the characteristics of the previous studies assessing serum calcium and risk of type 2 diabetes mellitus**

<table>
<thead>
<tr>
<th>Author (Ref)</th>
<th>Study</th>
<th>Number of Participants</th>
<th>Male (%)</th>
<th>Mean Age (yrs)</th>
<th>Follow-up (yrs)</th>
<th>Population Sample</th>
<th>Exposure definition</th>
<th>Exposure assessment</th>
<th>Endpoint definition</th>
<th>Endpoint ascertainment</th>
<th>Confounders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Becerra-Tomas (18)</td>
<td>Prospective Cohort</td>
<td>Spain, 2014</td>
<td>707</td>
<td>77</td>
<td>40</td>
<td>67</td>
<td>4.78 (median) Interquartile Range: 2.60-5.74</td>
<td>Post-hoc analysis of PREDIMED randomized clinical trial with available data on calcaemia.</td>
<td>Fasting albumin-corrected calcemia* Reference range 2.05–2.58 mmol/L</td>
<td>American Diabetes Association criteria†</td>
<td>Blood test of subjects with medical records positive for T2DM</td>
</tr>
<tr>
<td>Jorde (16)</td>
<td>Prospective Cohort</td>
<td>Norway, 2013</td>
<td>25657</td>
<td>705</td>
<td>48</td>
<td>47</td>
<td>8 (median)</td>
<td>Subjects 25-97 year-old participating in the 4th (1994-5) survey of the Tromsø population-based prospective study and followed up to the 6th (2007-8) survey</td>
<td>Nonfasting total calcemia Reference range 2.20-2.60 mmol/L</td>
<td>Not reported</td>
<td>Self-reported, registries, or HbA1c&gt;6.5%</td>
</tr>
<tr>
<td>Lorenzo (17)</td>
<td>Prospective Cohort</td>
<td>US, 2014</td>
<td>863</td>
<td>140</td>
<td>40</td>
<td>55</td>
<td>5.2 (mean) Range: 4.5-6.6</td>
<td>Subjects 40-69 year-old participating in the Insulin Resistance Atherosclerosis Study (IRAS) study</td>
<td>Fasting albumin-corrected calcemia*‡ Reference range 2.05–2.58 mmol/L</td>
<td>American Diabetes Association criteria‡, drug Rx</td>
<td>Blood test of subjects attending the 5-year follow-up visit of the IRAS study</td>
</tr>
</tbody>
</table>

* Albumin-corrected calcium (mmol/L) = calcium (mmol/L) + 0.2× (40–albumin [g/L])
† Fasting Plasma Glucose ≥126.0 mg/dL (7 mmol/L) or 2h plasma glucose ≥200 mg/dL (11.1 mmol/L) after a 75-g oral glucose load
‡ A nonlinear association between total serum calcium and risk of diabetes has also been reported
Supplemental Figure S1: Association between serum calcemia and risk of type 2 diabetes mellitus in three prospective available studies

Becerra-Tomas [18]  
Jorde [16]  
Lorenzo [17]

Dotted vertical lines indicate reference values

Supplemental Figure S2: Albumin-calcium binding capacity and albumin-adjusted calcium estimation

The formula to calculate albumin-adjusted serum calcium ([Total calcium (mg/dL) + 0.8 (4.0 - serum albumin (g/dL))] is based on several assumption. In particular, it assumes that 1 g/dL albumin binds approximately 0.8 mg/dL. However, in many circumstances, this ratio is modified by concomitant factors. For example, increased concentration of circulating fatty acids results in an increased albumin-to-calcium binding capacity and in a poor correlation of total calcium with direct measurements of iCa.

In this graph, assuming a total calcium level of 9.5 mg/dL (2.37 mmol/L) and a normal level of albumin (4 g/dL), the two lines show the estimated albumin-adjusted serum calcium accounting (solid red line) and not accounting (dotted black line) for a potential increase of calcium-to-albumin binding (x axis). Δ indicates the difference between the two estimates.
## Table 1: Baseline characteristics of the study population (N=2350) according to incident (Yes) and non-incident (No) cases of type 2 diabetes.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total (N=2350)</th>
<th>Yes (N=140)</th>
<th>No (N=2210)</th>
<th>(a) p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>52.9</td>
<td>53.3</td>
<td>52.9</td>
<td>0.361</td>
</tr>
<tr>
<td>Body mass index (kg/m(^2))</td>
<td>26.7</td>
<td>29.0</td>
<td>26.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>134</td>
<td>134</td>
<td>133</td>
<td>0.499</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/L)</td>
<td>4.04</td>
<td>4.09</td>
<td>4.04</td>
<td>0.555</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>1.30</td>
<td>1.21</td>
<td>1.30</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglycerides (mmol/L) (b)</td>
<td>1.11</td>
<td>1.45</td>
<td>1.09</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting plasma glucose (mmol/L)</td>
<td>4.58</td>
<td>4.92</td>
<td>4.56</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>C-reactive protein (mg/L) (b)</td>
<td>1.26</td>
<td>1.68</td>
<td>1.23</td>
<td>0.020</td>
</tr>
<tr>
<td>HOMA-IR (b)</td>
<td>2.20</td>
<td>3.17</td>
<td>2.16</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking (yes) (c)</td>
<td>33%</td>
<td>34%</td>
<td>33%</td>
<td>0.817</td>
</tr>
<tr>
<td>Family history of diabetes (yes) (c)</td>
<td>27%</td>
<td>30%</td>
<td>27%</td>
<td>0.366</td>
</tr>
<tr>
<td>Education (years) (b)</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>0.117</td>
</tr>
<tr>
<td>Alcohol (g/week) (b)</td>
<td>32</td>
<td>39</td>
<td>31</td>
<td>0.907</td>
</tr>
<tr>
<td>Physical activity (kcal/day) (b)</td>
<td>285</td>
<td>275</td>
<td>287</td>
<td>0.735</td>
</tr>
<tr>
<td>Serum active calcium (mmol/L)</td>
<td>1.18</td>
<td>1.17</td>
<td>1.18</td>
<td>0.587</td>
</tr>
</tbody>
</table>

HOMA-IR: Homeostatic model assessment of insulin resistance

\(a\) Difference Yes vs No

\(b\) Data reported as median and interquartile range

\(c\) Data reported as %
Figure 1: Hazard ratios and 95% confidence interval (bars) of type 2 diabetes mellitus by quartiles of baseline active calcium levels.

Model 1

Model 2

Model 3a

Model 3b

Hazard Ratio

Hazard Ratio

Hazard Ratio

Hazard Ratio

$\text{Active Calcium (mmol/L)}$

$\text{Active Calcium (mmol/L)}$

$\text{Active Calcium (mmol/L)}$

$\text{Active Calcium (mmol/L)}$

$p=0.538^*$

$p=0.389$

$p=0.557$

$p=0.330$

* $p$-value for trend